metformin and glucose, (beta-d)-isomer

metformin has been researched along with glucose, (beta-d)-isomer in 278 studies

Research

Studies (278)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.36)	18.2507
2000's	2 (0.72)	29.6817
2010's	197 (70.86)	24.3611
2020's	78 (28.06)	2.80

Authors

Authors	Studies
Chansouria, JP; Jahromi, MA; Manickam, M; Ramanathan, M; Ray, AB	1
Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V	1
Calado, J	1
Aragão, DM; da Costa, JC; Garcia, RM; Guarize, L; Lanini, J; Scio, E	1
Bailey, CJ; Bastien, A; Gross, JL; List, JF; Pieters, A	1
Boulton, DW; Griffen, SC; Kasichayanula, S; LaCreta, FP; Li, T; Liu, X; Pfister, M; Shyu, WC; Zhang, W	1
Del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, MA; Parikh, SJ; Rohwedder, K	1
Bolinder, J; Johansson, L; Kullberg, J; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sugg, J; Wilding, J	1
Hennicken, D; Henry, RR; List, JF; Marmolejo, MH; Murray, AV; Ptaszynska, A	1
Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y	1
Capuano, G; Nicolle, LE; Usiskin, K; Ways, K	1
Bolinder, J; Johansson, L; Langkilde, AM; Ljunggren, Ö; Parikh, S; Sjöström, CD; Sugg, J; Wilding, J	2
Collins, C; Kadokura, T; Smulders, RA; van Bruijnsvoort, M; van Dijk, J; Veltkamp, SA	1
Dhanjal, P; Ferrannini, E; Fonseca, VA; Houzer, A; Wilding, JP; Wilpshaar, W	1
Plosker, GL	1
Broedl, UC; Dieterich, S; Macha, S; Mattheus, M; Seman, LJ; Woerle, HJ	1
Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ	1
Bailey, CJ; Gross, JL; Hennicken, D; Iqbal, N; List, JF; Mansfield, TA	1
Pahor, A; Parikh, S; Rohwedder, K; Soler, NG; Sugg, J; Wilding, JP; Woo, V	1
Del Prato, S; Nauck, M	1
del Prato, S; Durán-García, S; Elze, M; Meier, JJ; Nauck, M; Parikh, SJ; Rohwedder, K	1
Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J	1
Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W	1
Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH	1
Hach, T; Hantel, S; Jelaska, A; Pinnetti, S; Rosenstock, J; Seman, LJ; Woerle, HJ	1
Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ	1
Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V	1
Broedl, UC; Häring, HU; Meinicke, T; Merker, L; Seewaldt-Becker, E; Weimer, M; Woerle, HJ	2
Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C	1
Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C	1
Bilo, HJ; Drion, I; Goudswaard, AN; Holleman, F; Kleefstra, N; van Hateren, KJ	1
Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP	1
Hardy, E; Jabbour, SA; Parikh, S; Sugg, J	1
Berk, A; Broedl, UC; Ferrannini, E; Hach, T; Hantel, S; Pinnetti, S; Woerle, HJ	1
Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S	1
Barnett, AH; Goring, S; Hawkins, N; Roudaut, M; Townsend, R; Wood, I; Wygant, G	1
Capuano, G; Fung, A; Nicolle, LE; Usiskin, K	1
Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J	1
Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD	1
Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J	1
Baldi, S; Broedl, UC; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Woerle, HJ	1
Seufert, J	1
Schnell, O	1
Grandy, S; Langkilde, AM; Parikh, S; Sjöström, CD; Sugg, JE	1
Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF	1
Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J	1
Ferrannini, E; Mari, A; Polidori, D	1
Pafili, K; Papanas, N	1
Bergenheim, K; Ekman, M; Granström, O; McEwan, P; Sabale, U	1
Del Prato, S; Durán-García, S; Langkilde, AM; Nauck, MA; Parikh, SJ; Rohwedder, K; Sugg, J	1
Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S	1
Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ	1
Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS	1
Andersen, KR; Broedl, UC; Kim, G; Ridderstråle, M; Woerle, HJ; Zeller, C	1
Tahrani, AA	1
Doggrell, SA; Tuli, R	1
Dou, J; Lu, J; Zhang, Q	1
Beckers, J; Hrabé de Angelis, M; Huypens, P; Neschen, S; Rathkolb, B; Scheerer, M; Schultheiss, J; Seelig, A; Suhre, K; Wolf, E; Wu, M; Wurst, W	1
Apanovitch, AM; de Bruin, TW; Johnsson, KM; List, JF; Parikh, SJ; Ptaszynska, A	1
Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N	1
Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G	1
Burgess, L; de Bruin, TW; Hamer-Maansson, JE; Hruba, V; Korányi, L; Schumm-Draeger, PM	1
Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH	1
Bennett, H; Bergenheim, K; McEwan, P; Ward, T	1
Jabbour, S	1
Cook, W; Hansen, L; Hirshberg, B; Iqbal, N; Li, Y; Rosenstock, J; Zee, P	1
Bailey, CJ; List, JF; Morales Villegas, EC; Ptaszynska, A; Tang, W; Woo, V	1
Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K	1
Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS	1
Doggrell, S	1
Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ	1
Bowering, K; Grohl, A; Matthaei, S; Parikh, S; Rohwedder, K	1
Frías, JP; Lewin, AJ	1
Abdul-Ghani, M	1
Del Prato, S; Durán-Garcia, S; Maffei, L; Nauck, M; Parikh, S; Rohwedder, K; Theuerkauf, A	1
Rupprecht, H	1
Araki, E; Broedl, UC; Kim, G; Koiwai, K; Salsali, A; Tanaka, Y; Taniguchi, A; Tanizawa, Y; Woerle, HJ	1
Blevins, T	1
Prázný, M; Slíva, J	1
Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R	2
Broedl, UC; Cescutti, J; Meinicke, T; Ross, S; Thamer, C; Woerle, HJ	1
Broedl, UC; Christiansen, AV; Häring, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ	1
Boulton, DW; Chang, M; Cui, D; Griffen, SC; LaCreta, F; Liang, D; Liu, X; Lubin, S; Quamina-Edghill, D	1
Broedl, UC; Christiansen, AV; Kim, G; Kovacs, CS; Merker, L; Roux, F; Salsali, A; Seshiah, V; Stella, P; Woerle, HJ	1
Fukase, H; Harigai, M; Iida, S; Ikeda, S; Kasahara, N; Miyata, K; Ohba, Y; Saito, T; Takano, Y; Terao, K	1
Beck, A; Beyer, U; Boerlin, V; Christ, AD; Ciorciaro, C; Cynshi, O; Ikeda, S; Kadowaki, T; Meyer, M; Takano, Y; Tanaka, R	1
Bowering, K; Johnsson, E; Matthaei, S; Parikh, S; Rohwedder, K; Sugg, J	1
Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Li, D; Mathieu, C; Ranetti, AE	1
Broedl, UC; Christiansen, AV; Haering, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ	1
Catrinoiu, D; Celiński, A; Chen, H; Cook, W; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Matthaei, S	1
Chirila, C; Davenport, E; Hach, T; Kaschinski, D; Palencia, R; Pfarr, E; Zheng, Q	1
Jia, Y; Lee, JH; Lee, SJ; Seo, WD; Wu, C	1
Grandy, S; Rohwedder, K; Ryden, A; Sternhufvud, C; Sugg, J	1
Hu, J; Tan, X	1
Yacoub, T	1
Han, P; Iqbal, N; Johnsson, E; Mansfield, T; Min, KW; Ptaszynska, A; T'Joen, C; Wang, B; Yang, W	1
Boulton, DW; Chang, M; Griffen, SC; Kitaura, C; LaCreta, F; Lubin, S; Pollack, A	1
McGuire, DK; Neeland, IJ; Salahuddin, U	1
Astiarraga, B; Barsotti, E; Broedl, UC; Ferrannini, E; Heise, T; Mari, A; Muscelli, E; Nosek, L; Schliess, F; Woerle, HJ	1
Huang, Y; Lai, D; Yang, X; Ye, Y; Yu, B; Zhong, X	1
Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ	1
Kamaruddin, NA; Kori, N; Mohd Noor, N; Mustafa, N; Othman, H; Rajoo, S; Sukor, N; Wahab, NA; Wan Seman, WJ	1
Shyangdan, DS; Uthman, OA; Waugh, N	1
Link, J; Macha, S; Meinicke, T; Rojas, C	1
Geissel, W	1
Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A	1
Hemmingsen, B; Krogh, J; Metzendorf, MI; Richter, B	1
Gupta, Y; Kalra, S; Kishor, K	1
de Bruin, TW; Hamer-Maansson, JE; Parikh, S; Reele, S; Tang, W	1
Farooq, S; Islam, N; Kiran, Z; Rashid, O	1
Edelsberger, T	1
Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S	1
Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH	1
Valek, R; Von der Mark, J	1
Kourlaba, G; Maniadakis, N; Tentolouris, N; Tzanetakos, C	1
Crowe, S; Hach, T; Lee, J; Nishimura, R; Salsali, A; Woerle, HJ; Yoon, KH	1
Ayoub, BM	2
Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R	1
Cha, BS; Chuang, LM; Kokubo, S; Lu, CH; Min, KW; Yoshida, S	1
Naito, T; Okamoto, A; Sanada, H; Yokokawa, H	1
Chen, H; Garcia-Sanchez, R; González González, JG; Hansen, L; Herrera Marmolejo, M; Iqbal, N; Johnsson, E; Mathieu, C	1
Aggarwal, N; Chen, H; Chin, A; Garcia-Hernandez, P; Hansen, L; Iqbal, N; Johnsson, E; Matthaei, S	1
Bloch, MJ	1
Broedl, UC; Hadjadj, S; Meinicke, T; Rosenstock, J; Woerle, HJ	1
Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U	1
Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I	1
Broedl, UC; Heer, M; Heise, T; Jordan, J; Lund, SS; Macha, S; Mattheus, M; Wanner, C; Woerle, HJ	1
Wise, J	1
Broedl, UC; Gallwitz, B; Götz, S; Maldonado-Lutomirsky, M; Nordaby, M; Tinahones, FJ; Woerle, HJ	1
Hu, J; Tan, X; Zhang, S; Zhou, M; Zou, P	1
Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E	1
Davidson, JA; Sloan, L	1
Buchholt, AT; El Khoury, AC; Kamal, A; Schubert, A; Taieb, V	1
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D	1
Lingvay, I	1
Jain, RK	1
Ayoub, BM; Mowaka, S	1
Higashi, Y; Ikehara, Y; Inoue, T; Kawaguchi, A; Kimura, K; Machii, N; Maruhashi, T; Matsuzawa, Y; Node, K; Okada, Y; Oyama, JI; Sakuma, M; Sato, Y; Shima, KR; Shimabukuro, M; Sugiyama, S; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamaoka-Tojo, M; Yoshida, H	1
Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N	1
Hashimoto, N; Horikoshi, T; Ishikawa, K; Ishikawa, T; Kobayashi, K; Koshizaka, M; Kuribayashi, N; Nagashima, K; Sato, Y; Shimofusa, R; Takahashi, S; Takemoto, M; Tatsuno, I; Terano, T; Uchida, D; Yokote, K	1
Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N	1
Hua, WC; Li, CM; Liu, Q; Wang, H; Wang, LG	1
Amadid, H; Færch, K; Jørgensen, ME; Karstoft, K; Nielsen, LB; Persson, F; Ried-Larsen, M	1
Drexler, A	1
Broedl, UC; Heer, M; Heise, T; Heusser, K; Jordan, J; Lund, SS; Macha, S; Mattheus, M; Tank, J; Wanner, C; Woerle, HJ	1
Aronson, R; Brown, RE; Gupta, N	1
Coppenrath, VA; Hydery, T	1
Colman, PG; Costello, AJ; Kumar, S	1
Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P	1
Bhatt, DL; Bonaca, MP; Cahn, A; Gause-Nilsson, IAM; Johansson, PA; Kato, ET; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Silverman, MG; Wilding, JPH; Wiviott, SD	1
Bell, KF; Chakravarty, A; Dhankhar, P; Rastogi, M	1
Chen, H; Del Prato, S; Garcia-Sanchez, R; Hansen, L; Iqbal, N; Johnsson, E; Mathieu, C; Rosenstock, J	1
Albiero, M; Avogaro, A; Bonora, BM; Bortolozzi, M; Cappellari, R; Ceolotto, G; Fadini, GP; Menegazzo, L; Romanato, F; Scattolini, V; Vigili de Kreutzeberg, S	1
Eckel, RH; Koh, KK; Lim, S	1
Chatsudthipong, V; Chattipakorn, N; Chueakula, N; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Thongnak, L; Wanchai, K	1
Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H	1
Bell, KF; Eudicone, JM; Gani, R; Huang, H; Krukas-Hampel, MR; Tugwell, CW	1
Aiello, V; Brancato, D; Di Noto, A; Fleres, M; Provenzano, F; Provenzano, V; Saura, G; Scorsone, A; Spano, L	1
Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH	1
Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C	1
Csomós, K; Cypryk, K; Dronamraju, N; Garcia-Sanchez, R; Jacob, S; Johnsson, E; Kellerer, M; Kurlyandskaya, R; Müller-Wieland, D; Rohwedder, K; Seufert, J; Sjöström, CD; Skripova, D	1
DeFronzo, RA; Kohler, S; Lee, C	1
Dunham, MW; Hurren, KM	1
Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ	1
Fawzy, MG; Mahrouse, MA; Moussa, BA	2
Scheen, AJ	1
Frias, JP; McPheeters, JT; Parker, ED; Wittbrodt, ET	1
Henry, RR; Katz, A; Klein, D; Mansfield, T; Pettus, J; Shi, L; Strange, P; Zhou, R; Zhuplatov, SB	1
Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK	1
Chen, H; Garcia-Sanchez, R; Mathieu, C; Rosenstock, J; Saraiva, GL	1
Orlova, VL; Shestakova, MV; Tretter, R; Verbovoy, AF; Wilding, JPH; Wilpshaar, W	1
Del Prato, S; Garcia-Sanchez, R; Handelsman, Y; Iqbal, N; Johnsson, E; Kurlyandskaya, R; Mathieu, C; Rosenstock, J	1
Janež, A; Janić, M; Japelj, M; Juretič, A; Lunder, M; Šabovič, M	1
Åkerblom, A; Johansson, L; Karlsson, C; Latva-Rasku, A; Lisovskaja, V; Nuutila, P; Oldgren, J; Oscarsson, J	1
Donnan, K; Segar, L	1
Asseburg, C; Neslusan, C; Willis, M	1
Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W	1
Chin, KL; Hird, TR; Liew, D; Magliano, DJ; Ofori-Asenso, R; Si, S; Zoungas, S	1
Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T	1
Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K	2
García-Sánchez, R; Jacob, S; Johnsson, E; Perl, S; Rosenstock, J	1
Ahuja, S; Akhtar, A; Sah, SP; Uniyal, A	1
Abdullah, AM; Fakhre, NA; M Amin, KF	1
Barakat, GH; Elkady, EF; Hassib, ST; Taha, EA	1
Boulton, DW; Dayton, B; Engman, H; Tang, W; Zhu, Y	1
Chen, K; Jiang, Z; Liang, Y; Lu, M; Wang, Z; Zhou, J	1
Bhutani, R; Bodla, RB; Kant, R; Kapoor, G	1
de Campos, ML; Degaut, FLD; Dias, BCL; Fachi, MM; Peccinini, RG; Pontarolo, R	1
Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L	1
Shah, PA; Sharma, V; Shrivastav, PS; Yadav, MS	1
Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G	1
Bae, JC; Hwang, YC; Kim, HJ; Kim, JH; Kim, SY; Kwak, SH; Lee, EY; Lee, S; Suh, S; Won, JC	1
Chen, X; Ouyang, J; Wang, H; Yang, J; Yao, G	1
Bai, XY; Sun, Q; Tang, Y; Zhang, M; Zhou, QL; Zhou, YF	1
Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L	2
Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH	1
Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Karg, MV; Ott, C; Schmieder, RE; Striepe, K	1
Bjornstad, P; Nelson, RG; Pavkov, ME	1
Dronamraju, N; Ekholm, E; Garcia-Sanchez, R; Jabbour, SA; Johnsson, E; Lind, M; Vilsbøll, T	1
Ferrannini, E; Katsiki, N; Mazidi, M; Ofori-Asenso, R	1
Dronamraju, N; Frias, JP; Garcia-Sanchez, R; Gonzalez-Galvez, G; Johnsson, E; Maaske, J; Peters, AL; Simonson, DC; Testa, MA	1
Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C	1
Dronamraju, N; Garcia-Sanchez, R; Hockings, PD; Johansson, L; Johnsson, E; Maaske, J; Wilding, JPH	1
Fernandez-Fernandez, B; Ortiz, A; Porrini, E; Soler, MJ	1
van Bommel, EJM; van Raalte, DH	1
Cui, L; Hao, Z; Li, G; Sun, Y; Yan, D	1
Ai, M; Anai, M; Fujishiro, M; Inazawa, T; Inoue, M; Ishihara, H; Kitazawa, T; Kuroda, H; Ohashi, H; Seino, H; Yamada, M	1
Chellan, N; Cirilli, I; Dludla, PV; Essop, MF; Ghoor, S; Huisamen, B; Johnson, R; Louw, J; Marcheggiani, F; Mazibuko-Mbeje, SE; Muller, CJF; Nkambule, BB; Orlando, P; Silvestri, S; Tiano, L	1
Andreadou, I; Balampanis, K; Bamias, A; Birba, D; Dimitriadis, G; Ikonomidis, I; Iliodromitis, E; Kalogeris, A; Katogiannis, K; Kountouri, A; Kousathana, F; Lambadiari, V; Parissis, J; Pavlidis, G; Thymis, J	1
Anwar, MM; Awad, M; Carapinha, JL; Elebrashy, I; Elhadad, H; Elsisi, GH; Khattab, M; Wafa, A	1
Beetz, N; Bertulis, J; Lang, B; Lee, J; Lingvay, I; Lippert, C; Loley, C; Manning, LS; Schuler-Metz, A; Sennewald, R; Terada, D	1
Aronson, R; Gerstein, HC; Hall, S; Harris, S; Hramiak, I; Liu, YY; McInnes, N; Sigal, RJ; Sultan, F; Woo, V	1
Ahn, DJ; Lee, IH	1
Armstrong, GP	1
El-Domiaty, H; El-Nabi, SH; Fayez Ewida, S; Hanna, G; Saleh, S; Shabaan, A	1
Bobade, PS; Dhote, AM; Ganorkar, SB; Patil, MR; Sharma, SS; Shirkhedkar, AA	1
Rasouli, N	1
Chin, HJ; Ferrannini, E; Lim, S; Moon, JH; Shin, Y	1
Deng, X; Hu, S; Li, Z; Ma, Y; Wang, Y	1
Li, M; Song, J; Ying, M; Zhuang, Y	1
Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD	1
Capehorn, MS; Catarig, AM; Johansen, P; Lawson, J; Lingvay, I; Paine, A; Sandberg, A; Shaw, R	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D	1
Bengtsson, O; DeMets, DL; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Sabatine, MS; Sjöstrand, M; Solomon, SD	1
Davies, MJ; George, JT; Inzucchi, SE; Johansen, OE; Khunti, K; Sattar, N; Trivedi, P; Zwiener, I	1
Alegete, P; Boodida, S; Vankalapati, KR	2
Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ	1
Kurozumi, A; Okada, Y; Tanaka, Y	1
Aplin, AC; Castillo, JJ; Esser, N; Hackney, DJ; Hogan, MF; Hull, RL; Larmore, MJ; Mundinger, TO; Zraika, S	1
Elkind-Hirsch, KE; Harris, R; Seidemann, E	1
Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M	1
Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C	1
Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M	2
Bairaktari, E; Bletsa, E; Chasapi, S; Dafopoulos, P; Dimou, A; Ferrannini, E; Filippas-Dekouan, S; Kostara, C; Koutsovasilis, A; Pappa, E; Spyroulias, G; Tsimihodimos, V	1
Barreto, J; Bonilha, I; Breder, I; Breder, JC; Carvalho, LSF; Cavalcante, P; Cintra, RMR; de Lima-Junior, JC; do Carmo, HRP; Kimura-Medorima, ST; Moreira, C; Moura, FA; Munhoz, DB; Nadruz, W; Oliveira, DC; Quinaglia, T; Soares, AAS; Sposito, AC	1
Anumolu, PD; Cvs, S; Gurrala, S; Raj, S	1
Abd El-Hameed, AM; Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, AAG; Yousef, AI	1
Abou-Omar, MN; Alharthi, S; Attia, MS; Kenawy, M; Mohamed, EH; Youssef, AO	1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D	1
Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J	1
Barreto, J; Breder, I; Cintra, RM; de Carvalho, LSF; Guerra-Júnior, G; Kimura-Medorima, ST; Munhoz, DB; Muscelli, E; Nadruz, W; Quinaglia, T; Soares, AAS; Sposito, AC; Wolf, VLW	1
Andrews, S; Cheatham, B; Dobbins, R; Hanmant, B; Hussey, EK; O'Connor-Semmes, R; Sagar, K; Tao, W; Wilkison, WO	1
Higashi, Y; Node, K; Okada, Y; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S	1
Abushanab, D; Ademi, Z; Al-Badriyeh, D; Liew, D; Marquina, C	1
Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K	1
Frías, JP; Hockings, PD; Iqbal, N; Johansson, L; Maaske, J; Suchower, L; Wilding, JPH	1
Chenchula, S; Padmavathi, R; Varthya, SB	1
Abd El-Fattah, EE; Abd-Eldayem, MA; Abdelhamid, AM; Abou-Elrous, M; Amin, NA; El-Ahwany, E; Gaafar, AGA; Girgis, S; Gobba, NA; Hafez, AM; Saber, S; Shahien, MA; Shata, A; Youssef, ME	1
Abd El-Fattah, EE; Abd-Eldayem, MA; Abdelhamid, AM; Alqarni, M; Amin, NA; Batiha, GE; Eissa, H; El-Ahwany, E; Etman, MA; Gaafar, AGA; Kaddah, MMY; Obaidullah, AJ; Saber, S; Shahien, MA; Youssef, ME	1
Ferrannini, E; Lim, S; Shin, Y; Sohn, M	1
Cheng, L; Fan, Y; Fu, Q; Lin, W; Liu, F; Wu, X; Zhang, X; Zhou, L	1
Fan, X; Guo, F; Huang, F; Liu, Y; Qin, G; Song, Y; Zhao, L	1
García, Á; Gil-Rojas, Y; Lasalvia, P	1
Bi, Y; Cheng, H; Liu, J; Miao, Y; Ni, W; Wang, J; Zhang, B; Zhang, W; Zhang, Z	1
Frullone, S; Gambardella, J; Lombardi, A; Macina, G; Mone, P; Morgante, M; Pansini, A; Santulli, G	1
Barkatestrong/Strong, H; Khaladkar, K; Mohan, B; Suryawanshi, S	1
Cankar, M; France Štiglic, A; Janež, A; Janić, M; Jerin, A; Lunder, M; Šabovič, M; Šmid, J	1
Huh, Y; Kim, YS	1
Abdallah, DM; Ahmed, KA; El-Abhar, HS; Fleifel, AM; Soubh, AA	1
Ahn, SH; Cho, Y; Choi, YJ; Hong, S; Kim, SH; Lee, E; Lee, YH; Seo, DH; Seo, S; Suh, YJ	1
Abidi, H; Ahmed, M; Khan, A; Khan, IA	1
Aly, RG; Alzaim, I; El-Mallah, A; El-Yazbi, AF; Shaaban, HH; Wahid, A	1
Prázný, M	1
Aamir, AH; Ahmed, I; Asghar, A; Ghaffar, T; Ishtiaq, O; Khan, S; Kumar, S; Masood, F; Raja, UY; Randhawa, FA; Raza, A; Rehman, T; Sherin, A; Wahab, MU	1
Gustafson, KM; Kellon, EM	1

Reviews

38 review(s) available for metformin and glucose, (beta-d)-isomer

Article	Year
Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs : the investigational drugs journal, 2009, Volume: 12, Issue:12 Topics: Administration, Oral; Animals; Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2009
Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs, 2012, Dec-03, Volume: 72, Issue:17 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transport Proteins; Treatment Outcome	2012
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin]. Nederlands tijdschrift voor geneeskunde, 2013, Volume: 157, Issue:38 Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Netherlands; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss	2013
Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5 Topics: Administration, Oral; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2014
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes	2014
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139 Suppl 2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult	2014
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes research and clinical practice, 2014, Volume: 105, Issue:3 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2014
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug safety, 2014, Volume: 37, Issue:10 Topics: Benzhydryl Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged	2014
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes]. MMW Fortschritte der Medizin, 2015, Jan-19, Volume: 157, Issue:1 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2015
Combination therapy for type 2 diabetes: dapagliflozin plus metformin. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:1 Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2016
Dapagliflozin combination therapy in type 2 diabetes mellitus. Postgraduate medicine, 2016, Volume: 128, Issue:1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Treatment Outcome	2016
A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. Expert opinion on drug safety, 2016, Volume: 15, Issue:3 Topics: Adult; Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2016
Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. European journal of clinical pharmacology, 2016, Volume: 72, Issue:6 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Treatment Outcome	2016
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ open, 2016, Feb-24, Volume: 6, Issue:2 Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss	2016
Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2016, Apr-21, Volume: 4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fasting; Glucose Intolerance; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2016
The cardiovascular phenotype: impact on choice of glucose- lowering therapy. JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:4 Topics: Acarbose; Benzhydryl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Glucosides; Heart Rate; Humans; Hypoglycemic Agents; Metformin; Obesity; Phenotype	2016
Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:18 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2016
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in therapy, 2017, Volume: 34, Issue:1 Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2017
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Current medical research and opinion, 2017, Volume: 33, Issue:6 Topics: Bayes Theorem; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Arab Emirates	2017
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:7 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil	2017
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications. Current medicinal chemistry, 2018, Volume: 25, Issue:13 Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2	2018
A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 92 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin	2017
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:1 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Combinations; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Tablets	2018
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis, 2018, Volume: 272 Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. Diabetes care, 2018, Volume: 41, Issue:8 Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds	2018
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:10 Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Peptides; Sodium-Glucose Transporter 1; Venoms	2018
The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert opinion on drug safety, 2018, Volume: 17, Issue:8 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2018
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. European journal of pharmacology, 2019, Mar-05, Volume: 846 Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors	2019
Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. Diabetes research and clinical practice, 2019, Volume: 148 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors	2019
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. Journal of medical economics, 2019, Volume: 22, Issue:4 Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholesterol; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Health Expenditures; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sodium-Glucose Transporter 2 Inhibitors	2019
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ open, 2019, 07-23, Volume: 9, Issue:7 Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials. Postgraduate medicine, 2019, Volume: 131, Issue:8 Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes	2019
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:6 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome	2020
Pharmaceutical Analytical Profile for Novel SGL-2 Inhibitor: Dapagliflozin. Critical reviews in analytical chemistry, 2021, Volume: 51, Issue:8 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2021
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis. Medicine, 2020, Jul-24, Volume: 99, Issue:30 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. The Journal of clinical endocrinology and metabolism, 2020, 12-01, Volume: 105, Issue:12 Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Rationality, Efficacy, Tolerability of Empagliflozin Plus Linagliptin Combination for the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies. Current diabetes reviews, 2022, Volume: 18, Issue:4 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome	2022

Trials

146 trial(s) available for metformin and glucose, (beta-d)-isomer

Article	Year
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, Drug; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sodium-Glucose Transport Proteins; Weight Loss; Young Adult	2009
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet (London, England), 2010, Jun-26, Volume: 375, Issue:9733 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors	2010
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes, obesity & metabolism, 2011, Volume: 13, Issue:1 Topics: Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Young Adult	2011
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes care, 2011, Volume: 34, Issue:9 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Glipizide; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2011
Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:3 Topics: Adipose Tissue; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transport Proteins; Treatment Outcome	2012
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. International journal of clinical practice, 2012, Volume: 66, Issue:5 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult	2012
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes care, 2012, Volume: 35, Issue:6 Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult	2012
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Current medical research and opinion, 2012, Volume: 28, Issue:7 Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections	2012
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:11 Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Osteogenesis; Osteoporosis; Time Factors; Treatment Outcome	2012
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clinical therapeutics, 2012, Volume: 34, Issue:8 Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome	2012
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:5 Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; United States	2013
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:2 Topics: Adult; Analysis of Variance; Area Under Curve; Benzhydryl Compounds; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reference Values; Young Adult	2013
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nasopharyngitis; Republic of Korea; Russia; Sodium-Glucose Transporter 2 Inhibitors; Taiwan; Thirst; Treatment Outcome; Ukraine; Urination Disorders; Weight Loss	2013
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC medicine, 2013, Feb-20, Volume: 11 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Treatment Outcome	2013
[Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Long-Term Care; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2013
[Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1 Topics: Aged; Balanitis; Benzhydryl Compounds; Blood Glucose; Body Weight; Candidiasis, Vulvovaginal; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Glipizide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urinary Tract Infections	2013
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes care, 2013, Volume: 36, Issue:9 Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles	2013
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC pharmacology & toxicology, 2013, Apr-30, Volume: 14 Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prodrugs; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2013
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet (London, England), 2013, Sep-14, Volume: 382, Issue:9896 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult	2013
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:12 Topics: Analysis of Variance; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Hematocrit; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2013
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss	2014
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2 Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss	2014
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Urinary Tract Infections; Weight Loss	2014
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care, 2013, Volume: 36, Issue:11 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Sulfonylurea Compounds; Treatment Outcome	2013
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovascular diabetology, 2013, Sep-05, Volume: 12 Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Body Mass Index; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors; Treatment Outcome	2013
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia, 2013, Volume: 56, Issue:12 Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles	2013
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International journal of clinical practice, 2013, Volume: 67, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult	2013
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes care, 2014, Volume: 37, Issue:3 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Urinary Tract Infections; Weight Loss	2014
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:12 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles	2013
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes technology & therapeutics, 2014, Volume: 16, Issue:3 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2014
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgraduate medicine, 2014, Volume: 126, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult	2014
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:7 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Risk Assessment; Surveys and Questionnaires; Treatment Outcome; Weight Loss	2014
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Oxygen; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2014
Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. International journal of clinical practice, 2014, Volume: 68, Issue:4 Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Health Status; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Time Factors	2014
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. The American journal of managed care, 2014, Volume: 20, Issue:1 Suppl Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles	2014
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:5 Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss	2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia, 2014, Volume: 57, Issue:5 Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles	2014
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes care, 2014, Volume: 37, Issue:6 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Time Factors	2014
Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections	2014
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:3 Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes	2015
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes care, 2014, Volume: 37, Issue:7 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss	2014
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:11 Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss	2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome	2014
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. Metabolism: clinical and experimental, 2014, Volume: 63, Issue:10 Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2014
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1 Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam	2015
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:1 Topics: Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Feasibility Studies; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; South Africa	2015
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss	2015
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2015
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult	2015
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections	2015
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants. International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Canagliflozin; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Postprandial Period; Tablets; Therapeutic Equivalency; Thiophenes; Young Adult	2015
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss	2015
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections	2015
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:6 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glipizide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2015
Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7 Topics: Adult; Aged; Benzhydryl Compounds; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2015
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:7 Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss	2015
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:7 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Treatment Outcome	2015
Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:12 Topics: Aged; Benzhydryl Compounds; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Glucosides; Humans; Hyperglycemia; Hypertension; Hypoglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors	2015
Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clinical therapeutics, 2015, Jul-01, Volume: 37, Issue:7 Topics: Adult; Benzhydryl Compounds; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult	2015
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult	2015
A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs. Drug research, 2016, Volume: 66, Issue:2 Topics: 1-Deoxynojirimycin; Adult; Benzhydryl Compounds; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Inositol; Male; Metformin; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Urine; Young Adult	2016
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Fasting; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Ketones; Male; Metformin; Middle Aged	2015
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Urinary Tract Infections	2015
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes care, 2015, Volume: 38, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2015
Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes research and clinical practice, 2015, Volume: 110, Issue:1 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome	2015
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes care, 2015, Volume: 38, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2015
Patient-reported outcomes among patients with type 2 diabetes mellitus treated with dapagliflozin in a triple-therapy regimen for 52 weeks. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diagnostic Self Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Quality of Life; Sulfonylurea Compounds; Surveys and Questionnaires; Treatment Outcome	2016
Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. Journal of diabetes, 2016, Volume: 8, Issue:6 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos	2016
Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clinical therapeutics, 2016, Jan-01, Volume: 38, Issue:1 Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Brazil; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Fasting; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult	2016
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. Diabetologia, 2016, Volume: 59, Issue:4 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged	2016
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes & vascular disease research, 2016, Volume: 13, Issue:2 Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Weight Loss	2016
Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:6 Topics: Adult; Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult	2016
Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects. International journal of clinical pharmacology and therapeutics, 2016, Volume: 54, Issue:4 Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets	2016
[New attempt in a benefit evaluation]. MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Metformin; Sulfonylurea Compounds	2015
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovascular diabetology, 2016, Apr-04, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds	2016
Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clinical pharmacology in drug development, 2016, Volume: 5, Issue:2 Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Biological Availability; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult	2016
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. Journal of diabetes investigation, 2016, Volume: 7, Issue:4 Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome	2016
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:10 Topics: Asia; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome	2016
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial. Journal of diabetes investigation, 2016, Volume: 7, Issue:3 Topics: Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Thiophenes; Treatment Outcome	2016
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11 Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2016
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2016
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes care, 2016, Volume: 39, Issue:10 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2016
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes. Clinical therapeutics, 2016, Volume: 38, Issue:10 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors	2016
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:2 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pancreatitis; Reproductive Tract Infections; Treatment Outcome; Urinary Tract Infections	2017
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:3 Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovascular diabetology, 2017, Apr-12, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Endothelial Cells; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult	2017
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV BMJ open, 2017, 05-09, Volume: 7, Issue:5 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Metformin; Prospective Studies; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome	2017
Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial). BMJ open, 2017, 06-06, Volume: 7, Issue:5 Topics: Adult; Aged; Benzhydryl Compounds; Body Composition; Body Weight; Cardiovascular Diseases; Denmark; Double-Blind Method; Exercise; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Prediabetic State; Research Design; Risk Factors	2017
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. Journal of the American Society of Hypertension : JASH, 2017, Volume: 11, Issue:9 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Glucosides; Heart Rate; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscle, Skeletal; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System	2017
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6 Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides	2018
DECLARE-TIMI 58: Participants' baseline characteristics. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:5 Topics: Aged; Benzhydryl Compounds; Body Mass Index; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Multicenter Studies as Topic; Obesity; Prevalence; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors	2018
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6 Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta diabetologica, 2018, Volume: 55, Issue:6 Topics: Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Extracellular Traps; Female; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Neutrophils	2018
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:6 Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins	2018
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:10 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult	2018
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:11 Topics: Adamantane; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; Urinary Tract Infections	2018
Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. Advances in therapy, 2018, Volume: 35, Issue:7 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Treatment Outcome	2018
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:12 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome	2018
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial. Diabetes technology & therapeutics, 2018, Volume: 20, Issue:11 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Treatment Outcome; Young Adult	2018
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. BMJ open, 2018, 09-24, Volume: 8, Issue:9 Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Drug Monitoring; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Treatment Outcome	2018
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Archives of endocrinology and metabolism, 2018, Volume: 62, Issue:4 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Reproductive Tract Infections; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2018
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes research and clinical practice, 2018, Volume: 146 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Russia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome	2018
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome	2019
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus. Cardiovascular diabetology, 2018, 12-03, Volume: 17, Issue:1 Topics: Adult; Aged; Arteries; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Recovery of Function; Slovenia; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Vasodilation	2018
Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients-a description of the DAPACARD study. Upsala journal of medical sciences, 2019, Volume: 124, Issue:1 Topics: Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart; Heart Ventricles; Hospitalization; Humans; International Cooperation; Magnetic Resonance Imaging; Metformin; Myocardial Contraction; Nuclear Medicine; Outcome Assessment, Health Care; Perfusion; Positron-Emission Tomography; Risk; Sample Size; Sodium-Glucose Transporter 2	2019
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clinical endocrinology, 2019, Volume: 90, Issue:6 Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; Drug Administration Schedule; Female; Glucosides; Hormones; Humans; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Treatment Outcome; Young Adult	2019
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:8 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome	2019
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:9 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Urinary Tract Infections	2019
Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. Clinical therapeutics, 2019, Volume: 41, Issue:8 Topics: Adamantane; Adolescent; Adult; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Dipeptides; Drug Combinations; Female; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Tablets; Therapeutic Equivalency; Young Adult	2019
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study). Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:2 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Fasting; Female; Glucosides; Glycemic Control; Humans; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Republic of Korea; Young Adult	2020
Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutrition & diabetes, 2019, 11-04, Volume: 9, Issue:1 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sleep; Sleep Apnea, Obstructive; Treatment Outcome	2019
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney international, 2020, Volume: 97, Issue:1 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Gliclazide; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Kidney; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Vasoconstriction; Vasodilation	2020
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. European heart journal. Cardiovascular pharmacotherapy, 2020, 11-01, Volume: 6, Issue:6 Topics: Aged; Arterial Pressure; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glucosides; Humans; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness	2020
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:6 Topics: Adamantane; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Treatment Outcome	2020
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome	2020
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. Trials, 2020, Feb-14, Volume: 21, Issue:1 Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Mexico; Middle Aged; Obesity, Morbid; Prediabetic State; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome; Waist Circumference; Weight Loss; Young Adult	2020
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:7 Topics: Adamantane; Adipose Tissue; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Drug Therapy, Combination; Glucosides; Humans; Liver; Metformin	2020
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB). Diabetes, obesity & metabolism, 2020, Volume: 22, Issue:9 Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Metformin; Sulfonylurea Compounds; Treatment Outcome	2020
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatme Journal of the American Heart Association, 2020, 05-05, Volume: 9, Issue:9 Topics: Adult; Aged; Arterial Pressure; Arteries; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelial Cells; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycocalyx; Greece; Humans; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vascular Stiffness; Ventricular Function, Left	2020
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate medicine, 2020, Volume: 132, Issue:4 Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Male; Medication Adherence; Metformin; Middle Aged; Therapeutic Equivalency; Young Adult	2020
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. The Journal of clinical endocrinology and metabolism, 2020, 08-01, Volume: 105, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exercise; Female; Glucosides; Glycated Hemoglobin; Healthy Lifestyle; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Recurrence; Remission Induction; Secondary Prevention; Time Factors; Treatment Outcome	2020
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). Journal of diabetes investigation, 2021, Volume: 12, Issue:2 Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult	2021
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes care, 2020, Volume: 43, Issue:10 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. Diabetologia, 2021, Volume: 64, Issue:1 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Prediabetic State; Treatment Outcome	2021
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes care, 2020, Volume: 43, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Proportional Hazards Models; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome	2020
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:2 Topics: Aged; Benzhydryl Compounds; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2021
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:2 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State	2021
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. American journal of obstetrics & gynecology MFM, 2020, Volume: 2, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; Hypoglycemic Agents; Metformin; Overweight; Pregnancy; Prospective Studies; Single-Blind Method	2020
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome	2021
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:5 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult	2021
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:6 Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome	2021
Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. The Journal of clinical endocrinology and metabolism, 2021, 04-23, Volume: 106, Issue:5 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Greece; Humans; Male; Metabolome; Metformin; Middle Aged; Treatment Outcome; Urinalysis	2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular diabetology, 2021, 03-26, Volume: 20, Issue:1 Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Brazil; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucosides; Glyburide; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Vasodilation	2021
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:9 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome	2021
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. The Journal of clinical endocrinology and metabolism, 2021, 09-27, Volume: 106, Issue:10 Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult	2021
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. Nutrition & diabetes, 2021, 06-12, Volume: 11, Issue:1 Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Weight; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Female; Glucosides; Glyburide; Glycated Hemoglobin; Hand Strength; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome	2021
Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. BMC pharmacology & toxicology, 2021, 06-13, Volume: 22, Issue:1 Topics: Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Fasting; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Pyrazoles	2021
Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin. Cardiovascular diabetology, 2021, 07-31, Volume: 20, Issue:1 Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Japan; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2021
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovascular diabetology, 2021, 09-04, Volume: 20, Issue:1 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Germany; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Hypoglycemic Agents; Insulin Glargine; Linagliptin; Male; Metformin; Middle Aged; Prospective Studies; Renal Plasma Flow; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome	2021
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:1 Topics: Adamantane; Adipose Tissue; Adolescent; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Imaging; Metformin; Sulfonylurea Compounds; Treatment Outcome	2022
Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study. Diabetes care, 2022, 05-01, Volume: 45, Issue:5 Topics: Acarbose; Benzhydryl Compounds; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin	2022
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study. The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:4 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Prospective Studies; Pyrazoles; Treatment Outcome; Vildagliptin	2022
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes. Journal of diabetes research, 2022, Volume: 2022 Topics: Adult; Advanced Oxidation Protein Products; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Glutathione Peroxidase; Humans; Hypoglycemic Agents; Interleukin-6; Metformin; Middle Aged; Superoxide Dismutase	2022
Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population. Frontiers in endocrinology, 2022, Volume: 13 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pakistan; Vildagliptin	2022

Other Studies

95 other study(ies) available for metformin and glucose, (beta-d)-isomer

Article	Year
Antihyperglycemic activity of phenolics from Pterocarpus marsupium. Journal of natural products, 1997, Volume: 60, Issue:6 Topics: Animals; Benzofurans; Blood Glucose; Body Weight; Cresols; Diabetes Mellitus, Experimental; Female; Glucosides; Hypoglycemic Agents; Male; Metformin; Phenols; Plants, Medicinal; Rats; Stilbenes; Wood	1997
Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats. Journal of ethnopharmacology, 2010, Apr-21, Volume: 128, Issue:3 Topics: Alloxan; Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Cecropia Plant; Diabetes Mellitus; Diabetes Mellitus, Type 2; Flavonoids; Free Radical Scavengers; Glucose Tolerance Test; Glucosides; Glyburide; Hypoglycemic Agents; Male; Medicine, Traditional; Metformin; Phenols; Plant Extracts; Rats; Rats, Wistar	2010
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds	2013
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:7 Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid	2014
Tofogliflozin: the road goes ever on. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:9 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2014
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Primary care diabetes, 2015, Volume: 9, Issue:1 Topics: Benzhydryl Compounds; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality-Adjusted Life Years; Scandinavian and Nordic Countries; Sulfonylurea Compounds; Time Factors; Treatment Outcome	2015
SGLT-2 inhibitors as second-line therapy in type 2 diabetes. The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:9 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2014
Dapagliflozin--do we need it registered for type 2 diabetes? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:11 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice. Diabetes, 2015, Volume: 64, Issue:1 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemic Agents; Metformin; Mice, Knockout; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2015
Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK. PharmacoEconomics, 2015, Volume: 33, Issue:2 Topics: Adult; Aged; Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Models, Economic; Risk Factors; Sulfonylurea Compounds; United Kingdom	2015
Comment and response to: dapagliflozin - do we need it registered for type 2 diabetes? Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Author’s response. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:18 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pyrazines; Triazoles	2014
Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Benzhydryl Compounds; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Sulfonylurea Compounds	2015
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes care, 2015, Volume: 38, Issue:3 Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Humans; Male; Metformin	2015
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. Expert opinion on drug safety, 2015, Volume: 14, Issue:5 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Weight Loss	2015
[Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type]. Vnitrni lekarstvi, 2015, Volume: 61, Issue:2 Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Czech Republic; Diabetes Mellitus, Type 2; Drug Approval; European Union; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2015
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016, Volume: 25, Issue:5 Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Personal Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome	2016
Saponarin activates AMPK in a calcium-dependent manner and suppresses gluconeogenesis and increases glucose uptake via phosphorylation of CRTC2 and HDAC5. Bioorganic & medicinal chemistry letters, 2015, Nov-15, Volume: 25, Issue:22 Topics: AMP-Activated Protein Kinases; Apigenin; Benzimidazoles; Biphenyl Compounds; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cyclic AMP Response Element-Binding Protein; Enzyme Activators; Forkhead Box Protein O1; Forkhead Transcription Factors; Gluconeogenesis; Glucose; Glucose Transporter Type 4; Glucosides; Hep G2 Cells; Histone Deacetylases; Humans; Insulin Resistance; Metformin; Naphthalimides; Phosphorylation; Pyrones; Thiophenes; Transcription Factors	2015
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC health services research, 2015, Nov-05, Volume: 15 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sodium-Glucose Transport Proteins; State Medicine; United Kingdom	2015
Empagliflozin/metformin (Synjardy) for type 2 diabetes. The Medical letter on drugs and therapeutics, 2015, Dec-21, Volume: 57, Issue:1484 Topics: Benzhydryl Compounds; Biomarkers; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Drug Costs; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Selection; Risk Assessment; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2015
[New fixed combination in type 2 diabetes]. MMW Fortschritte der Medizin, 2016, Apr-14, Volume: 158, Issue:7 Topics: Administration, Oral; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2016
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin. BMJ case reports, 2016, May-13, Volume: 2016 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2016
[XIGDUO - fixed combination of the active ingredients dapagliflozin and metformin]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:3 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transport Proteins	2016
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Clinical therapeutics, 2016, Volume: 38, Issue:6 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones	2016
[Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2017, Volume: 112, Issue:2 Topics: Benzhydryl Compounds; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical drug investigation, 2016, Volume: 36, Issue:8 Topics: Aged; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucosides; Greece; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2016
Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2016, Nov-05, Volume: 168 Topics: Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Least-Squares Analysis; Limit of Detection; Metformin; Spectrophotometry; Tablets	2016
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies. Diabetes research and clinical practice, 2016, Volume: 116 Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin	2016
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients. Drugs in R&D, 2016, Volume: 16, Issue:3 Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1	2016
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension. Journal of the American Society of Hypertension : JASH, 2016, Volume: 10, Issue:3 Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Metformin; Off-Label Use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2016
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC health services research, 2016, 08-05, Volume: 16, Issue:a Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome	2016
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:10 Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones	2016
NICE recommends new triple therapy option for type 2 diabetes. BMJ (Clinical research ed.), 2016, Oct-09, Volume: 355 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Practice Guidelines as Topic; Sulfonylurea Compounds; United Kingdom	2016
Green Pharmaceutical Analysis of Drugs Coformulated with Highly Different Concentrations Using Spiking and Manipulation of Their Ratio Spectra. Journal of AOAC International, 2017, Jul-01, Volume: 100, Issue:4 Topics: Benzhydryl Compounds; Chemistry, Pharmaceutical; Glucosides; Green Chemistry Technology; Metformin; Spectrophotometry; Tablets	2017
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5 Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors	2017
Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:6 Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors	2017
LC-MS/MS Determination of Empagliflozin and Metformin. Journal of chromatographic science, 2017, Aug-01, Volume: 55, Issue:7 Topics: Benzhydryl Compounds; Chromatography, Liquid; Glucosides; Limit of Detection; Linear Models; Metformin; Reproducibility of Results; Tablets; Tandem Mass Spectrometry	2017
Reducing CV risk in diabetes: An ADA update. The Journal of family practice, 2017, Volume: 66, Issue:5 Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones	2017
Can we go beyond surrogates? Journal of diabetes, 2017, Volume: 9, Issue:11 Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors	2017
Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diabetes technology & therapeutics, 2017, Volume: 19, Issue:11 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canada; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome	2017
Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2017, Volume: 34, Issue:11 Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Fournier Gangrene; Genital Diseases, Male; Glucosides; Humans; Insulin; Male; Metformin; Scrotum	2017
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting. Journal of medical economics, 2018, Volume: 21, Issue:5 Topics: Benzhydryl Compounds; Blood Pressure; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Health Expenditures; Health Resources; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years; Sulfonylurea Compounds; Thiazolidinediones; United Nations; United States	2018
Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model. Biochimica et biophysica acta. Molecular basis of disease, 2018, Volume: 1864, Issue:6 Pt A Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Glucosides; Humans; Insulin; Insulin Resistance; Kidney; Kidney Diseases; Male; Metformin; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction; Sodium-Glucose Transporter 2	2018
A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes. The American journal of managed care, 2018, Volume: 24, Issue:8 Suppl Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Registries; Retrospective Studies; Treatment Outcome	2018
Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience. Journal of diabetes research, 2018, Volume: 2018 Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Treatment Outcome	2018
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Dec-05, Volume: 205 Topics: Benzhydryl Compounds; Canagliflozin; Drug Combinations; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets	2018
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:2 Topics: Adult; Benzhydryl Compounds; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Glucosides; Health Care Costs; Health Resources; Humans; Insurance Claim Review; Male; Medicare Part D; Metformin; Middle Aged; Patient Acceptance of Health Care; Retrospective Studies; Sitagliptin Phosphate; United States	2019
Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. Scientific reports, 2019, 03-01, Volume: 9, Issue:1 Topics: Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Humans; Metformin; Probability	2019
Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signalling. Pharmacological reports : PR, 2019, Volume: 71, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Cognition Disorders; Disease Models, Animal; Insulin; Insulin Resistance; Interleukin-6; Lipid Peroxidation; Lipids; Male; Maze Learning; Memory; Metformin; Mice; Signal Transduction; Thioctic Acid; Toll-Like Receptor 2; Zymosan	2019
Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2019, Nov-05, Volume: 222 Topics: Algorithms; Analysis of Variance; Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Tablets	2019
Validated Liquid Chromatographic Method for the Determination of (Canagliflozin, Dapagliflozin or Empagliflozin) and Metformin in the Presence of (1-Cyanoguanidine). Journal of chromatographic science, 2019, Aug-16, Volume: 57, Issue:8 Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Guanidines; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2019
Therapy of empagliflozin plus metformin on T2DM mice shows no higher amelioration for glucose and lipid metabolism than empagliflozin monotherapy. Life sciences, 2019, Sep-01, Volume: 232 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucosides; Lipid Metabolism; Male; Metformin; Mice; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome	2019
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design. Bioorganic chemistry, 2019, Volume: 91 Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines	2019
A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomedical chromatography : BMC, 2019, Volume: 33, Issue:11 Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Humans; Linear Models; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry	2019
Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2019, Oct-25, Volume: 175 Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Chromatography, Liquid; Glucosides; Humans; Limit of Detection; Metformin; Plasma; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Solid Phase Extraction; Tandem Mass Spectrometry	2019
Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation. Diabetes research and clinical practice, 2019, Volume: 157 Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2019
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clinical science (London, England : 1979), 2019, 12-12, Volume: 133, Issue:23 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeogenesis; Glucosides; Glycosuria; Insulin Resistance; Liver; Male; Metformin; Obesity; Pancreas; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors	2019
Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes? Kidney international, 2020, Volume: 97, Issue:1 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hemodynamics; Humans; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vasoconstriction; Vasodilation; Young Adult	2020
Dapagliflozin attenuates renal gluconeogenic enzyme expression in obese rats. The Journal of endocrinology, 2020, Volume: 245, Issue:2 Topics: Animals; Benzhydryl Compounds; Diet, High-Fat; Gluconeogenesis; Glucose-6-Phosphatase; Glucosides; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Proteins; Intracellular Signaling Peptides and Proteins; Kidney; Male; Metformin; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Wistar	2020
SGLT2i and postglomerular vasodilation. Kidney international, 2020, Volume: 97, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation	2020
The authors reply. Kidney international, 2020, Volume: 97, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Humans; Metformin; Sodium-Glucose Transporter 2; Vasoconstriction; Vasodilation	2020
Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients. Medical science monitor : international medical journal of experimental and clinical research, 2020, Apr-02, Volume: 26 Topics: Benzhydryl Compounds; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome	2020
The Combination Effect of Aspalathin and Phenylpyruvic Acid-2- Nutrients, 2020, Apr-20, Volume: 12, Issue:4 Topics: AMP-Activated Protein Kinase Kinases; Animals; Aspalathus; Cells, Cultured; Chalcones; DNA Damage; Energy Metabolism; Gene Expression; Glucose; Glucosides; Membrane Potential, Mitochondrial; Metformin; Myocytes, Cardiac; NADPH Oxidases; Oxidative Stress; Phenylpyruvic Acids; PPAR alpha; Protein Kinases; Rats; Reactive Oxygen Species	2020
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt. Journal of medical economics, 2020, Volume: 23, Issue:8 Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Egypt; Glucosides; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Economic; Renal Insufficiency; Sulfonylurea Compounds; Thiazolidinediones; Time Factors	2020
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report. Medicine, 2020, May-22, Volume: 99, Issue:21 Topics: Administration, Intravenous; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Fluid Therapy; Glucosides; Humans; Hypernatremia; Hypoglycemic Agents; Hypokalemia; Insulin; Intestinal Pseudo-Obstruction; Kidney Pelvis; Metformin; Patient Discharge; Sodium-Glucose Transporter 2 Inhibitors; Ureter; Withholding Treatment	2020
Empagliflozin-Mediated Lithium Excretion: A Case Study and Clinical Applications. The American journal of case reports, 2020, Jun-10, Volume: 21 Topics: Adult; Antimanic Agents; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Humans; Hypoglycemic Agents; Lithium Compounds; Male; Medication Adherence; Metformin; Psychotic Disorders; Sodium-Glucose Transporter 2 Inhibitors	2020
Dapagliflozin, a sodium glucose cotransporter 2 inhibitors, protects cardiovascular function in type-2 diabetic murine model. Journal of genetics, 2020, Volume: 99 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Glucosides; Metformin; Random Allocation; Rats; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides	2020
In brief: Trijardy XR - a new 3-drug combination for Type 2 diabetes. The Medical letter on drugs and therapeutics, 2020, Jun-01, Volume: 62, Issue:1599 Topics: Administration, Oral; Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Metformin	2020
An Escape From Diabetes. The Journal of clinical endocrinology and metabolism, 2020, 09-01, Volume: 105, Issue:9 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Insulin Glargine; Metformin	2020
Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinology and metabolism (Seoul, Korea), 2020, Volume: 35, Issue:2 Topics: Adult; Aged; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Young Adult	2020
Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus. Applied health economics and health policy, 2021, Volume: 19, Issue:1 Topics: Adamantane; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Glucosides; Humans; Metformin; Prospective Studies; Randomized Controlled Trials as Topic	2021
Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form. Biomedical chromatography : BMC, 2021, Volume: 35, Issue:4 Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Tablets	2021
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. Endocrine journal, 2021, Mar-28, Volume: 68, Issue:3 Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes	2021
SGLT2-i improves markers of islet endothelial cell function in db/db diabetic mice. The Journal of endocrinology, 2021, Volume: 248, Issue:2 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endothelial Cells; Glucosides; Hypoglycemic Agents; Insulin Secretion; Islets of Langerhans; Male; Metformin; Mice; Sodium-Glucose Transporter 2 Inhibitors	2021
Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin. Journal of chromatographic science, 2022, Jan-01, Volume: 60, Issue:1 Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Glucosides; Limit of Detection; Linagliptin; Metformin; Reproducibility of Results	2022
Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers. Biochemistry. Biokhimiia, 2021, Volume: 86, Issue:2 Topics: Animals; Chitosan; Diabetes Mellitus, Experimental; Glucose; Glucosides; Inflammation; Lipid Peroxidation; Liver; Male; Metformin; Nanoparticles; Niacinamide; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Stilbenes; Streptozocin	2021
Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2021, Jun-05, Volume: 200 Topics: Benzhydryl Compounds; Chromatography, High Pressure Liquid; Chromatography, Liquid; Freezing; Glucosides; Humans; Lipids; Metformin; Pharmaceutical Preparations; Reproducibility of Results; Tandem Mass Spectrometry	2021
Application of experimental design in HPLC method optimization and robustness for the simultaneous determination of canagliflozin, empagliflozin, linagliptin, and metformin in tablet. Biomedical chromatography : BMC, 2021, Volume: 35, Issue:10 Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Tablets	2021
First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis. Current problems in cardiology, 2022, Volume: 47, Issue:6 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Qatar	2022
Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022, Volume: 28, Issue:1 Topics: Australia; Benzhydryl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin	2022
Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride. Life sciences, 2021, Dec-01, Volume: 286 Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Benzhydryl Compounds; Carbon Tetrachloride; Drug Therapy, Combination; Female; Glucosides; Hepatocytes; Liver; Liver Cirrhosis; Male; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred BALB C; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Primary Cell Culture; Signal Transduction; Transcription Factor RelA	2021
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 145 Topics: Animals; Apoptosis; Autophagy; Benzhydryl Compounds; Carcinoma, Hepatocellular; Disease Progression; Glucosides; Hypoglycemic Agents; Liver Neoplasms; MAP Kinase Kinase Kinases; Metformin; Mice; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors	2022
Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects. Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:4 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate; Treatment Outcome	2022
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome. Scientific reports, 2021, 12-20, Volume: 11, Issue:1 Topics: Adult; Benzhydryl Compounds; Body Weight; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Monocytes	2021
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease. Bioengineered, 2022, Volume: 13, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Glucose; Glucosides; Humans; Hypoglycemic Agents; In Situ Hybridization, Fluorescence; Metformin; MicroRNAs; RNA, Circular; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin	2022
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia. Expert review of pharmacoeconomics & outcomes research, 2022, Volume: 22, Issue:6 Topics: Benzhydryl Compounds; Cardiovascular Diseases; Colombia; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years	2022
Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes care, 2022, 05-01, Volume: 45, Issue:5 Topics: Aged; Benzhydryl Compounds; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Frail Elderly; Glucosides; Heart Failure; Humans; Insulins; Metformin; Prospective Studies; Stroke Volume	2022
Stability-indicating HPLC method development and validation for simultaneous estimation of metformin, dapagliflozin, and saxagliptin in bulk drug and pharmaceutical dosage form. Biomedical chromatography : BMC, 2022, Volume: 36, Issue:7 Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Drug Stability; Glucosides; Metformin; Tablets	2022
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC primary care, 2022, 05-27, Volume: 23, Issue:1 Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metformin; Primary Health Care; Weight Loss	2022
Preferential effect of Montelukast on Dapagliflozin: Modulation of IRS-1/AKT/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model. Life sciences, 2022, Oct-15, Volume: 307 Topics: Acetates; Animals; Antioxidants; Benzhydryl Compounds; Blood Glucose; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endoplasmic Reticulum; Endoribonucleases; Glucose Transporter Type 4; Glucosides; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Leukotriene Antagonists; Metformin; Muscle, Skeletal; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Response Elements; Streptozocin; Sulfides	2022
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice. Yonsei medical journal, 2022, Volume: 63, Issue:9 Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Pyrimidines; Republic of Korea; Thiazolidinediones; Treatment Outcome	2022
Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. Life sciences, 2022, Nov-01, Volume: 308 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzhydryl Compounds; Biomarkers; Cholesterol; Cholic Acid; Diet, High-Fat; Fibrosis; Glucosides; Inflammation; Insulin Resistance; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats	2022
The position of SGLT2 inhibitors in current medical practice - update 2022. Vnitrni lekarstvi, 2022,Summer, Volume: 68, Issue:2 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2022
Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC endocrine disorders, 2022, Oct-13, Volume: 22, Issue:1 Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Prospective Studies; Sitagliptin Phosphate; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters	2022
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors. Open veterinary journal, 2023, Volume: 13, Issue:3 Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Horse Diseases; Horses; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors	2023